April 17, 2025
Glycomine secures $115m funding for Phase IIb trial of rare disease drug
US-based biotechnology company Glycomine has secured $115m in Series C funding to progress the mannose-1-phosphate replacement therapy GLM101 into a randomised Phase IIb trial.